Just saying, the growing unamortised value of capture costs circa 40 million by 2020 is fairly indicative of the cash drain for NEA … there's a hole in bucket dear Henry dear Henry ...
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
